Royalty Pharma plc Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | $0.99 | $0.99 | $0.99 |
Q2 2024 | 3 | $0.97 | $0.97 | $0.97 |
Q3 2024 | 5 | $0.89 | $0.95 | $0.93 |
Q4 2024 | 3 | $1.07 | $1.07 | $1.07 |
Q1 2025 | 4 | $1.01 | $1.01 | $1.01 |
Q2 2025 | 4 | $1.11 | $1.11 | $1.11 |
Q3 2025 | 4 | $1.10 | $1.10 | $1.10 |
Q4 2025 | 4 | $1.36 | $1.36 | $1.36 |
Royalty Pharma plc Earnings Date And Information
Royalty Pharma plc last posted its earnings results on Thursday, August 8th, 2024. The company reported $0.96 earnings per share for the quarter, missing analysts' consensus estimates of $0.965 by $0.005. The company had revenue of 537.27 M for the quarter and had revenue of 2.35 B for the year. Royalty Pharma plc has generated $3 earnings per share over the last year ($1.88 diluted earnings per share) and currently has a price-to-earnings ratio of 18.33. Royalty Pharma plc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based on prior year's report dates.
Royalty Pharma plc Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
08/08/2024 | Q2 2024 | $0.97 | $0.23 | -0.74 | $627.42 M | $537.27 M |
05/09/2024 | Q1 2024 | $0.99 | $0.01 | -0.98 | $567.98 M | |
02/15/2024 | Q4 2023 | $1.01 | $1.11 | 0.1 | $596.00 M | |
11/08/2023 | Q3 2023 | $0.81 | $0.16 | -0.65 | $631.74 M | $536.31 M |
08/08/2023 | Q2 2023 | $0.83 | $0.51 | -0.32 | $543.70 M | $538.20 M |
05/09/2023 | Q1 2023 | $1.32 | $0.76 | -0.56 | $683.97 M | |
02/15/2023 | Q4 2022 | $1.56 | -$1.38 | -2.94 | $565.75 M | |
11/08/2022 | Q3 2022 | $0.71 | $0.36 | -0.35 | $586.32 M | $573.46 M |
08/04/2022 | Q2 2022 | $0.78 | $0.50 | -0.28 | $528.36 M | $535.96 M |
05/05/2022 | Q1 2022 | $0.72 | -$0.07 | -0.79 | $562.05 M | |
02/15/2022 | Q4 2021 | $0.79 | $0.02 | -0.77 | $575.70 M | |
11/10/2021 | Q3 2021 | $0.69 | $0.24 | -0.45 | $563.10 M | $585.77 M |
08/11/2021 | Q2 2021 | $1.08 | $484.33 M | $554.96 M | ||
05/11/2021 | Q1 2021 | $0.18 | $573.03 M | |||
02/24/2021 | Q4 2020 | $0.44 | $571.00 M | |||
11/12/2020 | Q3 2020 | $0.79 | $451.66 M | $539.00 M | ||
08/12/2020 | Q2 2020 | $0.09 | $468.93 M | $510.93 M | ||
03/30/2020 | Q1 2020 | $0.20 | $500.88 M | |||
12/30/2019 | Q4 2019 | $4.01 | $457.49 M | |||
09/29/2019 | Q3 2019 | $1.15 | $464.28 M |
Royalty Pharma plc Earnings: Frequently Asked Questions
-
When is Royalty Pharma plc's earnings date?
Royalty Pharma plc has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off last year's report dates.
-
How can I listen to Royalty Pharma plc's earnings conference call?
The conference call for Royalty Pharma plc's latest earnings report can be listened to online.
-
How can I read Royalty Pharma plc's conference call transcript?
The conference call transcript for Royalty Pharma plc's latest earnings report can be read online.
-
How much revenue does Royalty Pharma plc generate each year?
Royalty Pharma plc (:RPRX) has a recorded annual revenue of $2.35 B.
-
How much profit does Royalty Pharma plc generate each year?
Royalty Pharma plc (:RPRX) has a recorded net income of $2.35 B. Royalty Pharma plc has generated $2.54 earnings per share over the last four quarters.
-
What is Royalty Pharma plc's price-to-earnings ratio?
Royalty Pharma plc (:RPRX) has a price-to-earnings ratio of 18.33 and price/earnings-to-growth ratio is -1.17.